Table IV.
Asian Cancer Research Group molecular subtypes and characteristics of gastric cancer patients.
| Clinicopathological factors | MSI, n (%) | MSS/EMT, n (%) | MSS/TP53+, n (%) | MSS/TP53−, n (%) | P-value |
|---|---|---|---|---|---|
| Sex | 0.818 | ||||
| Male | 8 (12.3) | 9 (13.8) | 7 (10.8) | 20 (30.8) | |
| Female | 6 (9.2) | 4 (6.2) | 3 (4.6) | 8 (12.3) | |
| Age/year | 0.066 | ||||
| ≤60 | 4 (6.2) | 10 (15.4) | 4 (6.2) | 16 (24.6) | |
| >60 | 10 (15.4) | 3 (4.6) | 6 (9.2) | 12 (18.5) | |
| Tumor location | 0.136 | ||||
| EGJ | 4 (6.2) | 9 (13.8) | 3 (4.6) | 13 (20.0) | |
| Distal stomach | 10 (15.4) | 4 (6.2) | 7 (10.8) | 15 (23.1) | |
| Lauren classification | 0.125 | ||||
| Diffuse | 3 (4.6) | 7 (10.8) | 3 (4.6) | 5 (7.7) | |
| Intestinal | 7 (10.8) | 4 (6.2) | 2 (3.1) | 16 (24.6) | |
| Mixed | 4 (6.2) | 2 (3.1) | 5 (7.7) | 7 (10.8) | |
| Adjuvant therapy | 0.996 | ||||
| XELOX | 7 (10.8) | 7 (10.8) | 5 (7.7) | 14 (21.5) | |
| SOX | 7 (10.8) | 6 (9.2) | 5 (7.7) | 14 (21.5) |
MSI, microsatellite instability; MSS, microsatellite stable; EMT, epithelial-mesenchymal transition; TP53, tumor protein 53; EGJ, gastro-esophageal junction; XELOX, capecitabine combined with oxaliplatin; SOX, S1 combined with oxaliplatin.